Biotechnology Acquisitions in Michigan

Showing 5 transactions.

  • Buyer
    NanoImaging Services, Ampersand Capital Partners
    Target
    Proteos, Inc.
    Industry
    Biotechnology
    Location
    Michigan, United States
    Type
    Addon

    NanoImaging Services (NIS), a cryo-electron microscopy services provider backed by Ampersand Capital Partners, has acquired Proteos, Inc., a Kalamazoo-based CRO specializing in recombinant protein and antibody production. The add-on acquisition integrates Proteos’ protein production capabilities with NIS’s cryo-EM services to create an end-to-end offering for structure-based drug discovery and protein production workflows.

  • Buyer
    Integrated DNA Technologies (IDT)
    Target
    Swift Biosciences
    Industry
    Biotechnology
    Location
    Michigan, United States
    Type
    Buyout

    Integrated DNA Technologies (IDT) has acquired Swift Biosciences, a developer of Next-Generation Sequencing (NGS) library preparation and enrichment kits. The acquisition brings Swift's library prep and enrichment portfolio and Ann Arbor-based team into IDT to expand IDT's NGS product offerings and accelerate growth in academic, translational, and clinical research markets. Financial terms were not disclosed.

  • Buyer
    Shionogi & Co., Ltd.
    Target
    Tetra Therapeutics
    Industry
    Biotechnology
    Location
    Michigan, United States
    Type
    Buyout

    Shionogi & Co., Ltd. agreed to acquire clinical-stage biopharmaceutical company Tetra Therapeutics, giving Shionogi global rights to Tetra's portfolio including BPN14770. The deal, announced May 26, 2020, is valued at up to $500 million in milestone and contingent payments.

  • Buyer
    Bio-Rad Laboratories, Inc.
    Target
    Celsee, Inc.
    Industry
    Biotechnology
    Location
    Michigan, United States
    Type
    Buyout

    Bio-Rad Laboratories has acquired Celsee, Inc., a developer of instruments and consumables for single-cell isolation, detection and analysis. The acquisition expands Bio‑Rad’s capabilities in single-cell analysis and precision medicine; terms were not disclosed.

  • Buyer
    StemBioSys, Inc.
    Target
    CARTOX, Inc.
    Industry
    Biotechnology
    Location
    Michigan, United States
    Type
    Buyout

    San Antonio-based StemBioSys acquired a majority stake in Ann Arbor startup Cartox, obtaining control with plans to purchase the remaining equity subject to milestones. The deal brings Cartox's cardiotoxicity imaging and assay capabilities together with StemBioSys's CELLvo extracellular matrix technology to accelerate commercial development of pre-clinical cardiac safety and efficacy screening solutions.

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.